PathAI’s AISight® Solution Earned the Distinction from the Annual Awards Program which Recognizes Innovation in the Life Sciences and Biotechnology Industries
Boston, MA, November 25, 2024 – PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that its AISight® solution has been awarded “Diagnostics Innovation of the Year” in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.
AISight®1 is a cloud-native intelligent enterprise workflow solution that powers the end-to-end digital pathology workflows and AI applications of leading laboratories and research centers. It serves as a central hub for case management, image management, and best-in-class AI tools. The robust digital pathology platform offers access to a broad set of algorithms trained on extensive data sets, powering various use cases including caseload balancing and assignment, image ingestion, image viewing, collaboration tools, and image and case management. The promise of digital pathology and AI is to provide more precise diagnostic results with faster turnaround times to inform patient care.
“We want to ensure that our technology improves pathology workflows, and the pathologist’s experience. We are empowering our partners through the integration of AISight® into their workflows, and together we are accelerating the adoption of digital pathology and AI,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “This is a meaningful award from BioTech Breakthrough. We will continue to work closely with key stakeholders to tailor our solutions to meet the specific needs of the pathology community, driving widespread adoption and maximizing the benefits of AI-powered pathology.”
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the world’s top companies, solutions and products in the life sciences and biotechnology markets today. This year’s program attracted thousands of nominations from over 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
“The potential impact of AISight® is profound with PathAI at the forefront of revolutionizing pathology and setting a new standard for AI-powered Image Management System (IMS) technology and novel tools for workflow efficiency and collaboration. I applaud PathAI for taking a unique and innovative path in the development of their IMS, building on their strong foundation in AI pathology,” said Bryan Vaughn, Managing Director, BioTech Breakthrough. “PathAI’s AISight® platform represents a significant breakthrough in the digital pathology field, integrating cutting-edge AI technology directly and seamlessly into an industry-leading IMS platform to deliver transformative, differentiated, and value-generating applications across the pathology laboratory. Congratulations to PathAI for AISight® - our pick for ‘Diagnostics Innovation of the Year!’”
Learn more about AISight® on PathAI’s website.
Footnotes
1 AISight is for research use only in the US and is not for use in diagnostic procedures.
About PathAI
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples, with the potential to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com.
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Immunology, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughAwards.com.
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
Boston, MA, November 25, 2024 – PathAI, a global leader in artificial intelligence (AI) and digital pathology solutions, today announced that its AISight® solution has been awarded “Diagnostics Innovation of the Year” in the fourth annual BioTech Breakthrough Awards program conducted by BioTech Breakthrough, a leading independent market intelligence organization that evaluates and recognizes standout life sciences and biotechnology companies, products, and services around the globe.
AISight®1 is a cloud-native intelligent enterprise workflow solution that powers the end-to-end digital pathology workflows and AI applications of leading laboratories and research centers. It serves as a central hub for case management, image management, and best-in-class AI tools. The robust digital pathology platform offers access to a broad set of algorithms trained on extensive data sets, powering various use cases including caseload balancing and assignment, image ingestion, image viewing, collaboration tools, and image and case management. The promise of digital pathology and AI is to provide more precise diagnostic results with faster turnaround times to inform patient care.
“We want to ensure that our technology improves pathology workflows, and the pathologist’s experience. We are empowering our partners through the integration of AISight® into their workflows, and together we are accelerating the adoption of digital pathology and AI,” said Andy Beck, MD, PhD, co-founder and CEO of PathAI. “This is a meaningful award from BioTech Breakthrough. We will continue to work closely with key stakeholders to tailor our solutions to meet the specific needs of the pathology community, driving widespread adoption and maximizing the benefits of AI-powered pathology.”
The mission of the annual BioTech Breakthrough Awards program is to conduct the industry’s most comprehensive analysis and evaluation of the world’s top companies, solutions and products in the life sciences and biotechnology markets today. This year’s program attracted thousands of nominations from over 14 different countries throughout the world, serving as a global recognition platform that encourages bold ideas and solutions that will shape the future of biotechnology.
“The potential impact of AISight® is profound with PathAI at the forefront of revolutionizing pathology and setting a new standard for AI-powered Image Management System (IMS) technology and novel tools for workflow efficiency and collaboration. I applaud PathAI for taking a unique and innovative path in the development of their IMS, building on their strong foundation in AI pathology,” said Bryan Vaughn, Managing Director, BioTech Breakthrough. “PathAI’s AISight® platform represents a significant breakthrough in the digital pathology field, integrating cutting-edge AI technology directly and seamlessly into an industry-leading IMS platform to deliver transformative, differentiated, and value-generating applications across the pathology laboratory. Congratulations to PathAI for AISight® - our pick for ‘Diagnostics Innovation of the Year!’”
Learn more about AISight® on PathAI’s website.
Footnotes
1 AISight is for research use only in the US and is not for use in diagnostic procedures.
About PathAI
PathAI is the only AI-focused technology company to provide comprehensive precision pathology solutions from wet lab services to algorithm deployment for clinical trials and laboratory use. Rigorously trained and validated with data from more than 15 million annotations, its AI-powered models can be leveraged to optimize the analysis of pathology samples, with the potential to improve efficiency and accuracy of pathology interpretation, as well as to better gauge therapeutic efficacy and accelerate drug development for complex diseases. PathAI is headquartered in Boston, MA. For more information, please visit www.pathai.com.
About BioTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the BioTech Breakthrough Awards program is devoted to honoring excellence in life science and biotechnology solutions, services and companies. The BioTech Breakthrough Awards provide public recognition for the achievements of biotechnology companies and products in categories including BioPharma, Genomics, Therapeutics, Immunology, Food Science and BioAgriculture, and more. For more information visit BioTechBreakthroughAwards.com.
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
Get In Touch
For media inquiries, please contact:
Maggie Naples
SVM Public Relations and Marketing Communications
[email protected]
+1 401-490-9700
Maggie Naples
SVM Public Relations and Marketing Communications
[email protected]
+1 401-490-9700
